Pesquise uma condição ou tema. Veja a associação, o grau, a fonte e o limite — sem discurso de vendas.
Grau A Evidência humana mais ampla e direta para a pergunta específica citada.
Grau B Contexto clínico, de registro, regulatório ou de qualidade útil para a leitura.
Grau C Sinal inicial, pré-clínico, mecanístico ou de estudo pequeno que exige limites claros.
Os graus descrevem o registro citado e apoiam o letramento em pesquisa. Eles não avaliam um material de mercado nem decidem uma questão de saúde.
Tema: Obesity · GLP-1 · Categoria: Obesity
Randomized clinical weight-loss research
STEP 1 studied once-weekly semaglutide plus lifestyle intervention in adults with overweight or obesity and reported substantial weight loss at 68 weeks.
Limite: The population, dose, product, follow-up and protocol were specific; this is not a marketplace-material assessment.
Fonte: STEP 1 · NEJM Ler fonte ↗
Tema: Obesity · cardiovascular outcomes · Categoria: Obesity
Cardiovascular outcomes trial signal
SELECT evaluated semaglutide in adults with overweight or obesity and established cardiovascular disease without diabetes, with a lower incidence of major adverse cardiovascular events.
Limite: An outcomes result in a defined population is not a general prevention promise or a quality claim about an unverified product.
Fonte: SELECT · NEJM Ler fonte ↗
Tema: Obesity · GLP-1 · Categoria: Obesity
Longer-duration clinical research association
STEP 5 reported two-year weight and safety outcomes under a defined randomized extension protocol.
Limite: Product, adherence and protocol were study-specific; persistence of a study signal is not a product-quality claim.
Fonte: STEP 5 · Nature Medicine Ler fonte ↗
Tema: Obesity · withdrawal literacy · Categoria: Obesity
Randomized treatment-withdrawal research
STEP 4 randomized adults after an initial semaglutide run-in and showed different weight trajectories after continued treatment versus withdrawal.
Limite: Run-in design and treatment context matter; this does not predict an individual response or support unsupervised use.
Fonte: STEP 4 · NEJM Ler fonte ↗
Tema: Diabetes · oral GLP-1 literacy · Categoria: Diabetes
Randomized diabetes efficacy research
PIONEER 1 compared oral semaglutide with placebo in adults with type 2 diabetes and reported HbA1c and weight endpoints.
Limite: An oral formulation and a diabetes trial do not establish equivalence to injectable products or to a research listing.
Fonte: PIONEER 1 · Diabetes Care Ler fonte ↗
Tema: Obesity · GLP-1 · Categoria: Obesity
Randomized clinical weight-loss research
SCALE Obesity and Prediabetes assessed liraglutide with lifestyle intervention over 56 weeks in adults with obesity or overweight and comorbidity.
Limite: The trial used a regulated product, eligibility criteria and monitored protocol; it cannot validate another source or route.
Fonte: SCALE · NEJM Ler fonte ↗
Tema: Obesity · GLP-1/GIP · Categoria: Obesity
Randomized phase 3 weight-loss research
SURMOUNT-1 reported weight outcomes for a defined phase 3 population with obesity or overweight and no diabetes.
Limite: This was not a head-to-head comparison in the cited trial; read population, dose and follow-up before generalizing.
Fonte: SURMOUNT-1 · PubMed Ler fonte ↗
Tema: Diabetes · cardiovascular outcomes · Categoria: Diabetes
Diabetes cardiovascular safety evidence
SURPASS-4 compared tirzepatide with insulin glargine in adults with type 2 diabetes at increased cardiovascular risk and reported clinical outcomes during follow-up.
Limite: The study was not designed as a definitive superiority cardiovascular-outcomes trial; association is not a personal treatment recommendation.
Fonte: SURPASS-4 · The Lancet Ler fonte ↗
Tema: Obesity · triple agonist · Categoria: Obesity
Early phase 2 clinical research
A phase 2 obesity study reported dose-ranging weight outcomes for retatrutide, an investigational triple agonist.
Limite: Investigational status, limited duration and protocol-specific safety mean this is not approval, routine-care guidance or a material-quality finding.
Fonte: Retatrutide phase 2 · NEJM Ler fonte ↗
Tema: Inflammation · arthritis · Categoria: Inflammation
Preclinical research interest
Reviews and animal studies describe adjuvant-arthritis models and inflammatory pathways; the signal is not human arthritis evidence.
Limite: No adequate clinical evidence establishes efficacy or safety for human arthritis; BPC-157 is not approved for standard medical use.
Fonte: 2025 literature review · PubMed Ler fonte ↗
Tema: Inflammation · gastrointestinal research · Categoria: Inflammation
Preclinical research interest
A review discusses NSAID-associated injury and rat models, including proposed nitric-oxide-related mechanisms.
Limite: Preclinical findings and review claims do not establish a human treatment pathway or dose.
Fonte: Review · PubMed Ler fonte ↗
Tema: Endocrine · growth-hormone research · Categoria: Endocrine
Preclinical growth-hormone secretagogue pharmacology
The foundational pharmacology paper describes ipamorelin as a selective growth-hormone secretagogue in experimental systems; it does not establish evidence for a CJC-1295/Ipamorelin combination.
Limite: Preclinical pharmacology does not establish efficacy, safety, dosing or quality for an Ipamorelin or CJC-1295 marketplace material.
Fonte: Ipamorelin foundational pharmacology · PubMed Ler fonte ↗
Tema: Tissue repair · skin research · Categoria: Tissue repair
Preclinical and formulation research interest
Reviews describe copper-peptide biology and experimental skin or wound models, including proposed extracellular-matrix effects.
Limite: Experimental biology is not evidence for an injectable, topical or compounded product, and does not establish human clinical benefit.
Fonte: GHK-Cu review · PubMed (PMID 29986520) Ler fonte ↗
Tema: Tissue repair · naming literacy · Categoria: Tissue repair
Identity and evidence distinction
Thymosin β4 has a research literature, while “TB-500” is a marketplace name that should not be treated as automatically identical to the studied molecule or formulation.
Limite: A name match does not prove sequence, identity, formulation, bioequivalence, safety or approval.
Fonte: Thymosin β4 review · PubMed Ler fonte ↗
Tema: Tissue repair · wound research · Categoria: Tissue repair
Preclinical and early clinical research interest
Research includes dermal repair models and early clinical studies; endpoints and formulations vary across the literature.
Limite: This is not a recommendation or proof for an unapproved product, route or indication.
Fonte: Review of models and early studies · PubMed Ler fonte ↗
Tema: Sleep · neuroendocrine research · Categoria: Sleep
Small human physiology study
A controlled study in healthy volunteers measured sleep-stage changes after episodic or continuous GHRH administration.
Limite: Small, protocol-specific physiology research cannot be treated as sleep-care guidance or evidence for a marketplace material.
Fonte: J Clin Endocrinol Metab · PubMed Ler fonte ↗
Tema: Quality · COA literacy · Categoria: Quality/COA
Biotechnological quality framework
The guideline defines specifications as tests, analytical procedures and acceptance criteria for biotechnological products.
Limite: A guideline does not turn an unnamed vendor document into a pass result or prove that a lab method was fit for purpose.
Fonte: ICH Q6B · official guideline Ler fonte ↗
Tema: Quality · analytical methods · Categoria: Quality/COA
Analytical-method literacy framework
Validation concepts help a reviewer ask what an analytical method can actually establish about identity, purity or an impurity.
Limite: A citation alone does not validate a vendor method or a specific lot, and the current revision should be checked.
Fonte: ICH Q2(R1) · official guideline Ler fonte ↗
Tema: Quality · records · Categoria: Quality/COA
Regulatory records framework
FDA guidance frames data integrity as complete, consistent and accurate data across the lifecycle, with controls around records and computerized systems.
Limite: A records framework cannot authenticate a PDF, laboratory or lot by itself; it gives reviewers questions to ask.
Fonte: FDA · Data Integrity and Compliance With Drug CGMP Ler fonte ↗
Tema: Quality · sterility · Categoria: Quality/COA
Compendial test literacy
USP sterility-test concepts illustrate why sterile-product claims depend on a defined method, sampling plan, controls and interpretation.
Limite: A sterility test is not a guarantee of asepsis, and a vendor saying “sterile” is not the same as a complete validated release system.
Fonte: USP–NF · <71> Sterility Tests Ler fonte ↗
Tema: Quality · endotoxin · Categoria: Quality/COA
Compendial endotoxin-test literacy
USP <85> describes bacterial endotoxin testing concepts and method suitability for applicable pharmaceutical materials.
Limite: A test name without lot-specific data, method details and acceptance criteria is not proof that a material is safe or suitable.
Fonte: USP–NF · <85> Bacterial Endotoxins Test Ler fonte ↗
Tema: Quality · synthetic manufacture · Categoria: Quality/COA
Regulatory quality framework
EMA guidance covers manufacture, characterization, specifications and analytical control for synthetic peptides.
Limite: This is not a consumer certificate, product approval, or finding about a particular supplier or lot.
Fonte: EMA synthetic-peptide guideline Ler fonte ↗
Tema: Quality · contamination control · Categoria: Quality/COA
Manufacturing quality framework
WHO guidance emphasizes contamination-control systems for sterile products, including microbial, particulate and endotoxin controls.
Limite: System guidance does not prove the status of a particular lot, facility or document.
Fonte: WHO TRS 1044 Annex 2 Ler fonte ↗
Tema: Compounding · regulatory pathway · Categoria: Compounding
Regulatory pathway information
FDA materials distinguish statutory conditions and roles for 503A and 503B compounding pathways.
Limite: High-level information, not legal advice, product approval or a quality finding.
Fonte: FDA · official overview Ler fonte ↗
Tema: Compounding · shortage status · Categoria: Compounding
Regulatory pathway information
Shortage-list status can affect certain compounding-copy restrictions while other conditions remain in force.
Limite: Live status must be rechecked; it does not erase other legal, prescribing or quality requirements.
Fonte: FDA · official statement Ler fonte ↗
Tema: Compounding · Brazil · Categoria: Compounding
Regulatory quality framework
The Brazilian resolution sets minimum good-practice requirements for pharmacy compounding within its scope.
Limite: The Portuguese official text and current amendments control; this is not a product assessment.
Fonte: Official ANVISA / Ministry text Ler fonte ↗
Tema: Registry · trial literacy · Categoria: Registry
Research registry infrastructure
Registry records expose study metadata, status and design fields for selected peptide and GLP-1 terms.
Limite: Registration is not results, approval, efficacy or evidence that a commercial material matches the study.
Fonte: US government registry API Ler fonte ↗
Tema: Registry · reporting literacy · Categoria: Registry
Research transparency framework
WHO standards explain why prospective registration and minimum trial data fields matter when interpreting clinical research claims.
Limite: Registration improves visibility but does not make a study well designed, completed or positive.
Fonte: WHO ICTRP · minimum data set Ler fonte ↗
Tema: Quality · regulatory boundary · Categoria: Quality/COA
Regulatory-risk literacy
FDA communications about unapproved and misbranded products show why a research label cannot substitute for an approved product pathway.
Limite: A warning page is not a determination about every seller or lot; check current official notices and local rules.
Fonte: FDA · online product safety Ler fonte ↗
Tema: Obesity · comparator literacy · Categoria: Obesity
Randomized head-to-head clinical research
STEP 8 compared once-weekly semaglutide with daily liraglutide and placebo in adults with overweight or obesity under a defined protocol.
Limite: Head-to-head results still depend on the study population, regimen, adherence and approved clinical context.
Fonte: STEP 8 · NEJM Ler fonte ↗
Tema: Diabetes · safety literacy · Categoria: Diabetes
Systematic review of randomized trials
A systematic review and meta-analysis can help readers locate adverse-event patterns across randomized semaglutide trials in type 2 diabetes.
Limite: Pooled estimates do not remove individual contraindications, monitoring needs or product-quality questions.
Fonte: Systematic review · Diabetes Care Ler fonte ↗
Tente obesidade, GLP-1, inflamação, qualidade, sono ou manipulação. Nenhum resultado não é prova de ausência.
Comece pela amostra gratuita e use o Manual de Campo para tornar repetíveis a revisão de COAs, o rastreamento de alegações e as regras de parada.